The contract award to Agenus Inc's subsidiary SaponiQx, in collaboration with Ginkgo Bioworks, for a significant amount of $31M over 5 years, directly impacts Agenus by potentially increasing its revenue and enhancing its reputation in the biotech and vaccine development sector. The focus on next-generation vaccine adjuvants using generative molecular design could position Agenus at the forefront of vaccine technology, likely leading to positive investor sentiment and a potential increase in stock price in the short term.